SCHEMBL3035919

SCHEMBL3035919

CC(C)(C)OC(=O)N1CCC(CNc2ccccn2)CC1

nearest known ligand 0.68

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 11/20 0.68
KDM4E B2RXH2 1/20 0.60
PKM P14618 1/20 0.60
GPR119 Q8TDV5 2/20 0.57
NOS2 P35228 1/20 0.54
PRMT5 O14744 1/20 0.54
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
TGFBR1 P36897 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13930889 0.85 GPR119 (0.56) GRIN2BKDM4EPKMGPR119NOS2
SCHEMBL19462008 0.84 KDM4E (0.52) GRIN2BKDM4EPKMGPR119PRMT5
SCHEMBL1087667 0.83 NOS2 (0.72) KDM4EPKMGPR119NOS2PRMT5
SCHEMBL22594810 0.83 KDM4E (0.59) GRIN2BKDM4EPKMGPR119TGFBR1
SCHEMBL28463063 0.82 PTPN2 (0.62) GPR119NOS2
SCHEMBL20203120 0.82 GRIN2B (0.55) GRIN2BKDM4EPKMGPR119NOS2
SCHEMBL20203119 0.82 GRIN2B (0.55) GRIN2BKDM4EPKMGPR119NOS2
SCHEMBL20189785 0.82 GRIN2B (0.55) GRIN2BKDM4EPKMGPR119NOS2
SCHEMBL4646351 0.82 KDM4E (0.53) GRIN2BKDM4EPKMGPR119PRMT5
SCHEMBL3779057 0.82 KDM4E (0.53) GRIN2BKDM4EPKMGPR119PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204275-A1 N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2010-08-12 US disclosed
US-7763621-B2 Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same GALAPAGOS SAS (FR) 2010-07-27 US disclosed
US-7763621-B2 Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same GALAPAGOS SAS (FR) 2010-07-27 US disclosed
EP-2183219-A2 N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2010-05-12 EP disclosed
US-7582640-B2 Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same GALAPAGOS SAS (FR) 2009-09-01 US disclosed
US-7582640-B2 Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same GALAPAGOS SAS (FR) 2009-09-01 US disclosed
US-20090149476-A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same GALAPAGOS SAS 2009-06-11 US disclosed
US-20090149476-A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same GALAPAGOS SAS 2009-06-11 US disclosed
EP-1565467-B1 NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME GALAPAGOS SAS (FR) 2009-05-20 EP disclosed
WO-2009016214-A2 N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2009-02-05 WO disclosed
US-20080221082-A1 Ligands of Integrin Receptors ABBOTT GMBH & CO. KG (DE) 2008-09-11 US disclosed
US-7105508-B1 Integrin receptors antagonists ABBOTT GMBH & CO. KG (DE) 2006-09-12 US disclosed
US-20040259864-A1 Substituted pyrimidinone derivatives as ligands of integrin receptors ABBOTT GMBH & CO. KG (DE) 2004-12-23 US disclosed
WO-2004048375-A1 NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME PROSKELIA SAS (FR) 2004-06-10 WO disclosed
EP-1362046-A1 SUBSTITUTED PYRIMIDINONE DERIVATIVES AS LIGANDS OF INTEGRIN RECEPTORS Abbott GmbH & Co. KG (DE) 2003-11-19 EP disclosed
CN-1374960-A novel integrin receptor antagonists BASF AG (DE) 2002-10-16 CN disclosed
WO-2002068410-A1 SUBSTITUTED PYRIMIDINONE DERIVATIVES AS LIGANDS OF INTEGRIN RECEPTORS ABBOTT GMBH & CO. KG (DE) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259864-A1 Substituted pyrimidinone derivatives as ligands of integrin receptors ITGB3, ITGA5, ITGB5 GRIN2B 512/4885KDM4E 3060/4885PKM 3799/4885
US-20090149476-A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same ADGRF1, C5AR2, ADGRE5 GRIN2B 712/4885KDM4E 4730/4885PKM 4192/4885
US-20080221082-A1 Ligands of Integrin Receptors ITGB3, ITGAV, ITGA2B GRIN2B 1632/4885KDM4E 4341/4885PKM 4368/4885
US-20100204275-A1 N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 GRIN2B 170/4885KDM4E 356/4885PKM 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.